Comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in the management of melanoma; a modelling study based on molecular mass and therapeutic pharmacological reaction

Sora Yasri1*, Viroj Wiwanitkit2

Abstract


Melanoma is an important deadly cancer that is hard to manage. In the present day, the
use of new combined chemotherapy drug is the new approach for managing melanoma. In
this study, we compared dabrafenib plus trametinib versus vemurafenib plus cobimetinib in
management of melanoma using a modelling study based on molecular mass and therapeutic
pharmacological reaction. According to this study, dabrafenib plus trametinib has higher
efficacy than vemurafenib plus cobimetinib in treatment of melanoma which is concordant
with previous in vivo observation.

Keywords:
Dabrafenib, Trametinib, Vemurafenib,
Cobimetinib, Melanoma

Citation:Yasri S, Wiwanitkit V. Comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in
the management of melanoma; a modelling study based on molecular mass and therapeutic pharmacological reaction. Geriatr
Persia. 2018;2:e02.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.